R&D channel feed

Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

Last year

Ace­lyrin says CRO Fortrea made er­rors in tri­al of lead im­munol­o­gy drug izok­ibep

Last year

De­spite fail­ing its PhII test, Xenon sees fu­ture for ma­jor de­pres­sion drug

Last year

Feng Zhang's lat­est gene edit­ing trawl reels in 188 new CRISPR sys­tems

Last year
Discovery
Cell/Gene Tx

Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Last year

Af­ter pulling Blenrep from US mar­kets, GSK plots a come­back with PhI­II mul­ti­ple myelo­ma tri­al suc­cess

Last year

Sanofi, Re­gen­eron say Dupix­ent suc­ceeds in an­oth­er late-stage COPD study, set­ting up fil­ing for FDA ap­proval

Last year
Pharma

En­trada's Duchenne study re­mains on hold in US as biotech com­pletes dos­ing of two co­horts in UK tri­al

Last year

Flag­ship-found­ed Evelo Bio­sciences will dis­solve af­ter find­ing no 'vi­able al­ter­na­tive'

Last year
People

FDA warns Cipla's al­buterol in­haler plant af­ter thou­sands of com­plaints

Last year
FDA+
Manufacturing

J&J, Gen­mab re­veal first-line da­ta for Darza­lex Faspro, plus new man­tle cell lym­phoma re­sults for Im­bru­vi­ca-Ven­clex­ta: #ASH23

Last year
Pharma

Mor­phoSys march­es ahead with plans to file myelofi­bro­sis drug de­spite mixed PhI­II re­sults

Last year

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

Last year
Financing
Startups

CAR-T cell ther­a­pies in­fused in­to brain shrink tu­mors in two glioblas­toma stud­ies

Last year
Cell/Gene Tx

'In­fe­ri­or ef­fi­ca­cy' leads to pre­ma­ture end of PhI­II for Bay­er's next-gen blood thin­ner asun­dex­i­an

Last year

Mer­ck cough drug fails to win ad­comm’s back­ing as FDA rais­es ef­fi­ca­cy ques­tions

Last year

Pfiz­er, Astel­las clinch ex­pand­ed ap­proval for Xtan­di in ear­li­er line of prostate can­cer

Last year
Pharma
FDA+

Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

Last year
Cell/Gene Tx

Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Last year
Manufacturing

Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

Last year

Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

Last year
Cell/Gene Tx

Spring­Works eyes US fil­ing for MEK in­hibitor af­ter pos­i­tive PhI­Ib da­ta in rare dis­ease

Last year

Scoop: Rakuten Med­ical tar­gets year-end close for $100M+ Se­ries E to fund pho­toim­munother­a­py pipeline: #Jef­feries23

Last year
Financing

Gen­er­ate:Bio­med­i­cines opens the hood on its AI soft­ware for mak­ing pro­teins

Last year
AI
First page Previous page 60616263646566 Next page Last page
A service from the Financial Times